{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T04:17:49Z","timestamp":1744431469953,"version":"3.40.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1053\/j.jvca.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T17:08:06Z","timestamp":1738688886000},"page":"1345-1347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pro: The Patient With the Recent Intake of DOACs Problems Are Solved With the Approval of Reversal Agents"],"prefix":"10.1053","volume":"39","author":[{"given":"Eleni","family":"Arnaoutoglou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9342","authenticated-orcid":false,"given":"Maria P.","family":"Ntalouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2025.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: Insights from the ARISTOTLE trial","volume":"36","author":"Held","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.02.002_bib0002","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.002_bib0003","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.002_bib0004","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal: Full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.002_bib0005","doi-asserted-by":"crossref","first-page":"ezad340","DOI":"10.1093\/ejcts\/ezad340","article-title":"Optimal management of cardiac surgery patients using direct oral anticoagulants: Recommendations for clinical practice","volume":"64","author":"Heuts","year":"2023","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.jvca.2025.02.002_bib0006","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/EJA.0000000000001968","article-title":"Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding","volume":"41","author":"Grottke","year":"2024","journal-title":"Eur J Anaesthesiol"},{"key":"10.1053\/j.jvca.2025.02.002_bib0007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/ejcts\/ezx325","article-title":"2017 EACTS\/EACTA guidelines on patient blood management for adult cardiac surgery","volume":"53","author":"Pagano","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.jvca.2025.02.002_bib0008","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: Sixth edition","volume":"27","author":"Rossaint","year":"2023","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2025.02.002_bib0009","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.002_bib0010","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/phar.2727","article-title":"Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures","volume":"42","author":"Bradshaw","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.jvca.2025.02.002_bib0011","doi-asserted-by":"crossref","first-page":"ezad100","DOI":"10.1093\/ejcts\/ezad100","article-title":"Andexanet alfa in acute aortic syndrome: First UK experience","volume":"63","author":"Al-Attar","year":"2023","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.jvca.2025.02.002_bib0012","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.jvca.2020.08.017","article-title":"Intraoperative off-label reversal of apixaban by andexanet alfa while on VA-ECMO immediately after emergent surgery for acute type A aortic dissection","volume":"35","author":"Kainz","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.02.002_bib0013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/02184923241237300","article-title":"Effective application of a direct-acting oral anticoagulants reversal agent in acute type A aortic dissection repair: A case report","volume":"32","author":"Wakami","year":"2024","journal-title":"Asian Cardiovasc Thorac Ann"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:39:32Z","timestamp":1744400372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077025001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1053077025001132"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2025.02.002","relation":{},"ISSN":["1053-0770"],"issn-type":[{"type":"print","value":"1053-0770"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pro: The Patient With the Recent Intake of DOACs Problems Are Solved With the Approval of Reversal Agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}